News 2020

Gatwick, January 08, 2020 – As the biggest insulin supplier in the UK and with 95 years of innovation in diabetes care, Novo Nordisk is committed to ensuring patients’medicine supplies are unaffected as a result of Brexit. Our priority is that our patients receive the care and treatment that they need.


Read more.....


This page is intended for UK consumer media, UK trade/medical media and members of the UK public.